”EVM16 contains neoantigens with high immunogenicity potential that are predicted based on the unique tumor mutations of each patient by Everest’s proprietary neoantigen prediction algorithm. “
Let’s hope in some good preliminary results!!
It’s for solid tumors I hope it will be tested on prostate cancer !